ArticleJournal of nanobiotechnology2023
Detoxified synthetic bacterial membrane vesicles as a vaccine platform against bacteria and SARS-CoV-2.
Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Review
- Targeting Outer Membrane Vesicles ofJournal of microbiology and biotechnology · 2026Review
- Tiny packages, big potential: bacterial membrane vesicles in vaccinology.Microbial cell factories · 2025Review
- Neutrophil-mediated delivery of hybrid cross-species nanovesicles for treatment of bacterial infections.Nature communications · 2025Article
- Two Sides of the Same Coin-Mechanistic Insight, Diagnostic Application and Therapeutic Translation of Bacterial and Host-Derived Extracellular Vesicles.Journal of extracellular biology · 2025Review
- Development of a Promising Bivalent Vaccine AgainstExploration (Beijing, China) · 2025Article
- The Lpp-OmpA-BtaE fusion protein causes a protective immune response against Brucella melitensis in mice.Scientific reports · 2025Article
- STING Agonist Drug Delivery by Bacterial Extracellular Vesicles Induces Synergistic Immuno-Oncology Responses and Efficient Inhibition of Tumour Growth.Journal of extracellular vesicles · 2025Article
- Systemic infection by Candida albicans requires FASN-α subunit induced cell wall remodeling to perturb immune response.PLoS pathogens · 2025Article
- Research progress on bacterial outer membrane vesicles in antibiotic resistance and clinical anti-infective therapy.Frontiers in microbiology · 2025Review
- Viral Mimetic Bacterial Outer Membrane Vesicles for Targeting Angiotensin-Converting Enzyme 2.International journal of nanomedicine · 2025Article
- Engineering strategies and biomedical applications of bacterial extracellular vesicles.Biomaterials translational · 2025Review
- Development of High-Production Bacterial Biomimetic Vesicles for Inducing Mucosal Immunity Against Avian PathogenicInternational journal of molecular sciences · 2024Article
- Structural stability for surface display of antigen 43 and application to bacterial outer membrane vesicles production.BMB reports · 2024Article
- The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.Virology journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of vaccines based on outer membrane vesicles (OMV) that naturally bud off from bacteria is an evolving field in infectious diseases. However, the inherent inflammatory nature of OMV limits their use as human vaccines. This study employed an engineered vesicle technology to develop synthetic bacterial vesicles (SyBV) that activate the immune system without the severe immunotoxicity of OMV. SyBV were generated from bacterial membranes through treatment with detergent and ionic stress. SyBV induced less inflammatory responses in macrophages and in mice compared to natural OMV. Immunization with SyBV or OMV induced comparable antigen-specific adaptive immunity. Specifically, immunization with Pseudomonas aeruginosa-derived SyBV protected mice against bacterial challenge, and this was accompanied by significant reduction in lung cell infiltration and inflammatory cytokines. Further, immunization with Escherichia coli-derived SyBV protected mice against E. coli sepsis, comparable to OMV-immunized group. The protective activity of SyBV was driven by the stimulation of B-cell and T-cell immunity. Also, SyBV were engineered to display the SARS-CoV-2 S1 protein on their surface, and these vesicles induced specific S1 protein antibody and T-cell responses. Collectively, these results demonstrate that SyBV may be a safe and efficient vaccine platform for the prevention of bacterial and viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.